<?xml version="1.0" encoding="utf-8"?>
<IndexPatientGuideline ID="x22745" Name="Guideline Statement 43" IsComponent="true" Changed="20260414T18:08:09" Created="20260414T18:06:33" Published="20260416T09:16:49" SiteBaseUrl="https://www.auanet.org" Locale="" XPowerPath="/Home/Guidelines &amp; Quality/Guidelines/Clinical Guidelines/Clinically Localized Prostate Cancer/Principles of Management/Principles of Radiation/Guideline Statement 43">
  <IGX_Categories Count="0" CategoryIds="" />
  <LingualMaps />
  <Header type="string" UID="faf9fd2842b549d09e761cd943c2be20" label="Header" readonly="false" hidden="false" required="false" indexable="false" CIID="">Guideline Statement 43</Header>
  <BodyCopy type="xhtml" UID="41a2d8598c364193bbfe9ad86d7bcd3c" label="Body Copy" readonly="false" hidden="false" required="false" indexable="false" Height="" CIID="">&lt;p&gt;&lt;strong&gt; &lt;/strong&gt;&lt;strong&gt;When combining ADT with radiation therapy, clinicians may use combined androgen suppression (LHRH agonist with an antiandrogen), an LHRH agonist alone, or an LHRH antagonist alone. &lt;em&gt;(Expert Opinion)&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;</BodyCopy>
  <DiscussionLinkName type="string" UID="b364402056154f78b38cd8d663eaf3ba" label="Discussion Link Name" readonly="false" hidden="false" required="false" indexable="false" CIID="">Discussion</DiscussionLinkName>
  <DiscussionTitle type="string" UID="ceedafe4ad314b5d8d3225bc0083b81c" label="Discussion Title" readonly="false" hidden="false" required="false" indexable="false" CIID="">Discussion</DiscussionTitle>
  <DiscussionBody type="xhtml" UID="9bbbac02721d4eefba59c63ee7ff9007" label="Discussion Body" readonly="false" hidden="false" required="false" indexable="false" Height="" CIID="">&lt;p&gt;Various compositions of ADT have been used in combination with radiation in randomized trials to date. For example, a number of studies used combined androgen suppression for the entire course of treatment,&lt;sup&gt;275, 276, 278, 292, 295&lt;/sup&gt; while other series used an LHRH agonist for the duration of treatment with an initial a short course of antiandrogen at the early phase of treatment,&lt;sup&gt;294, 296&lt;/sup&gt; and some trials used LHRH agonists alone.&lt;sup&gt;286, 289&lt;/sup&gt; The Panel believes that clinicians may use any one of these options in combination with radiation.&lt;/p&gt;</DiscussionBody>
</IndexPatientGuideline>